Protagonist Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
PTGX$136.26+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| · · · · · · · · · · · · · · · · · | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| · · · · · · Accumulated · · · · | |||||||||
| · · · · Additional · · Other · · · · Total | |||||||||
| · · Common · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||
| · · Stock · · Capital · · Income (Loss) · · Deficit · · Equity | |||||||||
| Three months ended June 30, 2024 | Shares | Amount | | | | | | | |
| Balance at March 31, 2024 | 58,600,787 | $1 | | $969,042 | $(229) | | $(408,370) | $560,444 | |
| Issuance of common stock under equity incentive and employee stock purchase plans | | 161,276 | — | | 2,572 | — | | — | 2,572 |
| Stock-based compensation expense | — | — | | 8,944 | — | | — | 8,944 | |
| Other comprehensive income (loss) | — | — | | — | (20) | | — | (20) | |
| Net income (loss) | — | — | | — | — | | (30,616) | (30,616) | |
| Balance at June 30, 2024 | 58,762,063 | $1 | | $980,558 | $(249) | | $(438,986) | $541,324 | |
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · Accumulated · · · · | |||||||||||||||||
| · · · · Additional · · Other · · · · Total | |||||||||||||||||
| · · Common · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · · Stock · · Capital · · Income (Loss) · · Deficit · · Equity | |||||||||||||||||
| Three months ended June 30, 2023 · Shares · Amount · · · · · · · | |||||||||||||||||
| Balance at March 31, 2023 | | 51,440,503 | | $1 | | $786,768 | | $(122) | | $(570,480) | | $216,167 | |||||
| Issuance of common stock pursuant to at-the-market offering, net of issuance costs | | 5,750,000 | | | — | | | 107,790 | | | — | | | — | | | 107,790 |
| Issuance of common stock under equity incentive and employee stock purchase plans | | 329,486 | — | | 973 | — | | — | 973 | ||||||||
| Shares withheld for net settlement of tax withholding upon vesting of restricted stock units | | (25,804) | | | — | | | (669) | | | — | | | — | | | (669) |
| Stock-based compensation expense | — | — | | 8,343 | — | | — | 8,343 | |||||||||
| Other comprehensive income (loss) | — | — | | — | (76) | | — | (76) | |||||||||
| Net income (loss) | — | — | | — | — | | (38,460) | (38,460) | |||||||||
| Balance at June 30, 2023 | 57,494,185 | $1 | | $903,205 | $(198) | | $(608,940) | $294,068 | |||||||||
PROTAGONIST THERAPEUTICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity (continued)
(In thousands, except share data)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · Accumulated · · · · | |||||||||||||||||
| · · · · Additional · · Other · · · · Total | |||||||||||||||||
| · · Common · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · · Stock · · Capital · · Income (Loss) · · Deficit · · Equity | |||||||||||||||||
| Six months ended June 30, 2024 · Shares · Amount · · · · · · · | |||||||||||||||||
| Balance at December 31, 2023 | 57,708,613 | $1 | | $952,491 | $(105) | | $(615,710) | $336,677 | |||||||||
| Issuance of common stock under equity incentive and employee stock purchase plans | | 989,254 | | | — | | | 10,371 | | | — | | | — | | | 10,371 |
| Shares withheld for net settlement of tax withholding upon vesting of restricted stock units | | (20,793) | | | — | | | (600) | | | — | | | — | | | (600) |
| Issuance of common stock upon exercise of Pre-Funded Warrants | | 84,989 | | | | | | — | | | | | | | | | — |
| Stock-based compensation expense | — | — | | 18,296 | — | | — | 18,296 | |||||||||
| Other comprehensive income (loss) | — | — | | — | (144) | | — | (144) | |||||||||
| Net income (loss) | — | — | | — | — | | 176,724 | 176,724 | |||||||||
| Balance at June 30, 2024 | 58,762,063 | $1 | | $980,558 | $(249) | | $(438,986) | $541,324 | |||||||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · Accumulated · · · · | |||||||||||||||||
| · · · · Additional · · Other · · · · Total | |||||||||||||||||
| · · Common · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · · Stock · · Capital · · Income (Loss) · · Deficit · · Equity | |||||||||||||||||
| Six months ended June 30, 2023 · Shares · Amount · · · · · · · | |||||||||||||||||
| Balance at December 31, 2022 | | 49,339,252 | | $— | | $752,722 | | $(359) | | $(536,755) | | $215,608 | |||||
| Issuance of common stock pursuant to public offering, net of issuance costs | | 5,750,000 | | | — | | | 107,790 | | | — | | | — | | | 107,790 |
| Issuance of common stock pursuant to at-the-market offering, net of issuance costs | | 1,749,199 | | | 1 | | | 24,301 | | | — | | | — | | | 24,302 |
| Issuance of common stock under equity incentive and employee stock purchase plans | 687,697 | — | | 3,234 | — | | — | 3,234 | |||||||||
| Shares withheld for net settlement of tax withholding upon vesting of restricted stock units | | (31,963) | | | — | | | (769) | | | — | | | — | | | (769) |
| Stock-based compensation expense | — | — | | 15,927 | — | | — | 15,927 | |||||||||
| Other comprehensive income (loss) | — | — | | — | 161 | | — | 161 | |||||||||
| Net income (loss) | — | — | | — | — | | (72,185) | (72,185) | |||||||||
| Balance at June 30, 2023 | 57,494,185 | $1 | | $903,205 | $(198) | | $(608,940) | $294,068 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.